Global API Intermediate Market is valued at approximately USD 139.4 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.4% over the forecast period 2023-2030. Active Pharmaceutical Ingredient (API) intermediates commonly referred to as drug intermediates, are chemical compounds or substances formed during the synthesis or manufacturing process of an API. The final active pharmaceutical component utilized in the formulation of medicines is produced from these intermediates, which are the essential building blocks or precursor molecules. API intermediates are used in developing novel pharmaceutical substances. The production of APIs uses compounds known as API intermediates as building blocks or precursors. The quality control processes use API intermediates as reference standards. The surge in demand for generic drugs, the rising trend of contract manufacturing and outsourcing, increase in the prevalence of chronic diseases such as cardiovascular disorders, diabetes, cancer, and respiratory ailments, coupled with the escalating geriatric populations are the key driving factors for the global API Intermediate Market.
In addition, the flourishing growth of the biopharmaceutical industry is acting as a catalyzing factor for the market demand during the estimated period. Biopharmaceuticals are a type of drug that is produced using biological materials, such as proteins, genes, and cells. Biological components including proteins, DNA, and cells are used to make biopharmaceuticals, a specific class of medication. These drugs are extremely popular and are more efficient than conventional small-molecule medicines. The expansion of the biopharmaceutical sector is boosting demand for API intermediates as they are necessary for the creation of biopharmaceuticals. As per Statista, in 2022, it was estimated that the biopharmaceuticals sector account for USD 403.1 billion globally, is expected to continue to grow, and is likely to surpass USD 974.5 billion by 2030. Hence, these factors are bolstering the growth of the API Intermediate Market in the estimated period 2023-2030. Moreover, the growing focus on personalized medicine, as well as increasing investments in research and development present various lucrative opportunities over the forecast years. However, the imposition of stringent government regulations and the limited availability of skilled labor and expertise are challenging the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global API Intermediate Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the regional pharmaceutical companies heavily investing in research and development activities to discover new drugs and improve existing drug formulations. Also, advances in pharmaceutical manufacturing techniques, such as continuous manufacturing and the use of process analytical technology (PAT), have improved the efficiency and quality of API production. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. Factors such as the rise in chronic diseases, spurring population, growing demand for affordable healthcare, and the expiration of patents for several branded drugs, along with the expansion of the pharmaceutical industry in emerging economies such as India and China are significantly propelling the market demand across the region.
Major market players included in this report are:
Anyang General Chemical Co., Ltd.
Evonik Industries AG
Sandoo Pharmaceuticals and Chemicals Co., Ltd.
Recent Developments in the Market:
Ø In March 2022, Sumitomo Chemical Co., Ltd., a Japanese chemical company announced that the company builds a new manufacturing facility for active pharmaceutical ingredients (APIs) and intermediates for small molecule drugs at its Oita Works (Oita City, Oita Prefecture, Japan) to increase its ability to meet the rising demand for small molecule drugs.
Global API Intermediate Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Type, Application, End User, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Bulk Drug Intermediates
By End User:
Biotech and Pharmaceutical Companies
Middle East & Africa
Rest of Middle East & Africa